

Pimecrolimus cream (Elidel[®])

(No. 35/03)

Novartis

Summary of Recommendation

9 August 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

Advice: following Independent Review Panel assessment.

Not recommended for use within NHS Scotland.

Pimecrolimus cream is the first topical immunomodulator licensed for the treatment of signs and symptoms of mild-to-moderate atopic dermatitis. There is no evidence that it has clinical advantage in terms of efficacy or safety when compared with the alternative treatments, which include mild-to-moderately potent topical corticosteroids. The economic case for using this preparation is unproven.

Professor David H Lawson
Chairman